ELSEVIER

Journal of Controlled Release 46 (1997) 291–292

journal of controlled release

Author Index Volume 46 (1997)

Adachi, I., see Viroonchatapan, E. (46) 263
Amidon, G.L., see Langguth, P. (46) 39
Amidon, G.L., see Walter, E. (46) 75
Baluom, M., see Rubinstein, A. (46) 59
Bodmeier, R., see Chang, C.-M. (46) 215
Bohner, V., see Langguth, P. (46) 39
Budd, G.C., see Saffran, M. (46) 89
Castellano, S., see Pellett, M.A. (46) 205
Chang, C.-M. and Bodmeier, R., Effect of dissolution media and additives on the drug release from cubic phase delivery systems (46) 215
Cho, A.-R., see Kim, M.-K. (46) 243
Chung, S.-J., see Kim, M.-K. (46) 243
Collett, J.H., see Munjeri, O. (46) 273
Couet, W., see Guédès, J.P. (46) 197
Crommelin, D.J.A., Daemen, T., Scherphof, G.L., Vingerhoeds, M.H., Heeremans, J.L.M., Kluft, C. and Storm, G., Liposomes: vehicles for the targeted and controlled delivery of peptides and proteins (46) 165
Croyle, M.A., see Walter, E. (46) 75
Daemen, T., see Crommelin, D.J.A. (46) 165
David, A., see Rubinstein, A. (46) 59
Davidson, B.L., see Walter, E. (46) 75
Davidson, D., see Meehan, E. (46) 107
Davis, A.F., see Pellett, M.A. (46) 205
Domb, A., see Peracchia, M.T. (46) 223
Enhsen, A., see Kramer, W. (46) 17
Falk, E., see Kramer, W. (46) 17
Fell, J.T., see Munjeri, O. (46) 273
Friden, P.M., Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood–brain barrier (46) 117
Friedman, M., see Rubinstein, A. (46) 59
Fujita, T., see Muranishi, S. (46) 157
Gliko-Kabir, I., see Rubinstein, A. (46) 59
Gref, R., see Peracchia, M.T. (46) 223
Gross, Y., see Meehan, E. (46) 107
Guédès, J.P. and Couet, W., Simulation of the effect of variable duration of absorption on steady-state plasma levels of drugs administered orally as zero-order delivery systems (46) 197
Hadgraft, J., see Pellett, M.A. (46) 205
Hashida, M., Hirabayashi, H., Nishikawa, M. and Takakura, Y., Targeted delivery of drugs and proteins to the liver via receptor-mediated endocytosis (46) 129
Hediger, M.A., see Nussberger, S. (46) 31
Heeremans, J.L.M., see Crommelin, D.J.A. (46) 165
Heizmann, J., see Langguth, P. (46) 39
Higashi, Y., see Yen, W.-C. (46) 5
Hilfinger, J.M., see Walter, E. (46) 75
Hirabayashi, H., see Hashida, M. (46) 129
Hoffmann, A., see Kramer, W. (46) 17
Horikoshi, I., see Viroonchatapan, E. (46) 263
Ikada, Y., see Nakaoka, R. (46) 253
Kim, M.-K., Chung, S.-J., Lee, M.-H., Cho, A.-R. and Shim, C.-K., Targeted and sustained delivery of hydrocortisone to normal and stratum corneum-removed skin without enhanced skin absorption using a liposome gel (46) 243
Kluft, C., see Crommelin, D.J.A. (46) 165
Kramer, W., Wess, G., Enhsen, A., Falk, E., Hoffmann, A., Neckermann, G., Schubert, G. and Urmann, M., Modified bile acids as carriers for peptides and drugs (46) 17
Langer, R., see Peracchia, M.T. (46) 223
Langguth, P., Bohner, V., Heizmann, J., Merkle, H.P., Wolffram, S., Amidon, G.L. and Yamashita, S., The challenge of proteolytic enzymes in intestinal peptide delivery (46) 39
Lee, M.-H., see Kim, M.-K. (46) 243
Lee, V.H.L., see Yen, W.-C. (46) 5
Lotan, N., see Peracchia, M.T. (46) 223
Martin, M., see Meehan, E. (46) 107
Meehan, E., Gross, Y., Davidson, D., Martin, M. and Tsals, I., A microinfusor device for the delivery of therapeutic levels of peptides and macromolecules (46) 107
Meijer, D.K.F. and Swart, P.J., Isolated perfused liver as a tool to study the disposition of peptides, liver first-pass effects, and cell-specific drug delivery (46) 139
Merkle, H.P., see Langguth, P. (46) 39
Minamitake, Y., see Peracchia, M.T. (46) 223
Munjeri, O., Collett, J.H. and Fell, J.T., Hydrogel beads based on amidated pectins for colon-specific drug delivery: the role of chitosan in modifying drug release (46) 273
Murakami, M., see Muranishi, S. (46) 157
Muranishi, S., Fujita, T., Murakami, M. and Yamamoto, A., Potential for lymphatic targeting of peptides (46) 157
Nakaoka, R., Tabata, Y., Yamaoka, T. and Ikada, Y., Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification (46) 253
Nassar, T., see Rubinstein, A. (46) 59
Neckermann, G., see Kramer, W. (46) 17

Neubert, R., see Schmalfuß, U. (46) 279
Nishikawa, M., see Hashida, M. (46) 129
Nussberger, S., Steel, A. and Hediger, M.A., Structure and pharmacology of proton-linked peptide transporters (46) 31
Pansky, B., see Saffran, M. (46) 89
Pellett, M.A., Castellano, S., Hadgraft, J. and Davis, A.F., The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro (46) 205
Peracchia, M.T., Gref, R., Minamitake, Y., Domb, A., Lotan, N. and Langer, R., PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: Investigation of their drug encapsulation and release characteristics (46) 223
Radai, R., see Rubinstein, A. (46) 59
Roessler, B.J., see Walter, E. (46) 75
Rubinstein, A., Tirosh, B., Baluom, M., Nassar, T., David, A., Radai, R., Gliko-Kabir, I. and Friedman, M., The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools (46) 59
Saffran, M., Pansky, B., Budd, G.C. and Williams, F.E., Insulin and the gastrointestinal tract (46) 89
Sato, H., see Viroonchatapan, E. (46) 263
Scherphof, G.L., see Crommelin, D.J.A. (46) 165
Schmalfuß, U., Neubert, R. and Wohlrab, W., Modification of drug penetration into human skin using microemulsions (46) 279
Schubert, G., see Kramer, W. (46) 17
Shim, C.-K., see Kim, M.-K. (46) 243
Smith, P.L., Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery (46) 99
Steel, A., see Nussberger, S. (46) 31
Storm, G., see Crommelin, D.J.A. (46) 165
Swart, P.J., see Meijer, D.K.F. (46) 139
Szentkuti, L., Light microscopical observations on luminally administered dyes, dextrans, nanospheres and microspheres in the pre-epithelial mucus gel layer of the rat distal colon (46) 233
Tabata, Y., see Nakaoka, R. (46) 253
Takakura, Y., see Hashida, M. (46) 129
Tazawa, K., see Viroonchatapan, E. (46) 263
Tirosh, B., see Rubinstein, A. (46) 59
Tsals, I., see Meehan, E. (46) 107
Ueno, M., see Viroonchatapan, E. (46) 263
Urmann, M., see Kramer, W. (46) 17
Vingerhoeds, M.H., see Crommelin, D.J.A. (46) 165
Viroonchatapan, E., Sato, H., Ueno, M., Adachi, I., Tazawa, K. and Horikoshi, I., Release of 5-fluorouracil from thermosensitive magnetoliposomes induced by an electromagnetic field (46) 263
Walter, E., Croyle, M.A., Davidson, B.L., Roessler, B.J., Hilfinger, J.M. and Amidon, G.L., Adenovirus mediated gene transfer to intestinal epithelial cells as a potential approach for oral delivery of peptides and proteins (46) 75
Wess, G., see Kramer, W. (46) 17
Williams, F.E., see Saffran, M. (46) 89
Wohlrab, W., see Schmalfuß, U. (46) 279
Wolffram, S., see Langguth, P. (46) 39
Yamamoto, A., see Muranishi, S. (46) 157
Yamaoka, T., see Nakaoka, R. (46) 253
Yamashita, S., see Langguth, P. (46) 39
Yen, W.-C., Higashi, Y. and Lee, V.H.L., Intestinal paracellular peptide transport: mobilization of intracellular calcium as a mechanism of tight junctional opening by 4-phenylazobenzoxycarbonyl–Pro–Leu–Gly–Pro–D-Arg (Pz-peptide) in the rabbit descending colon and Caco-2 cell monolayers (46) 5

ELSEVIER

Journal of Controlled Release 46 (1997) 293–294

journal of controlled release

Subject Index Volume 46 (1997)

Absorption, (46) 99, (46) 197
Acinar distribution of asialoglycoprotein receptor, (46) 139
Adenovirus, (46) 75
Aerosol, (46) 99
Amidated pectins, (46) 273
Anti-HIV preparation, (46) 139
Antibody conjugate, (46) 117
Antiviral proteins, (46) 139
AZT, (46) 139
Bile acid transport systems, (46) 17
Binding capability, (46) 233
Bioavailability, (46) 39
Biopharmaceutics, (46) 197
Blood–brain barrier, (46) 117
Body distribution, (46) 253
Caco-2, (46) 75
Chemical modification, (46) 253
Chitosan, (46) 273
Cholesterol, (46) 279
Colon, (46) 59, (46) 89
Controlled release, (46) 39
Cubic phase, (46) 215
Cytostatics, (46) 165
Delivery, (46) 99
Dextran magnetite, (46) 263
Dogs, (46) 89
Donor phase temperature, (46) 205
Drug delivery, (46) 31, (46) 107, (46) 117, (46) 273
Drug release, (46) 263
Drug targeting to liver, (46) 139
Drug targeting, (46) 17, (46) 157, (46) 165
Electromagnetic induction heating, (46) 263
Epithelial cell gene transfer, (46) 75
FiTC-Dextrans and Latex nano- and microspheres, (46) 233
Fibrinolysis, (46) 165
5-Fluorouracil, (46) 263
GI insulin, (46) 89
Galactosylated macromolecules, (46) 129
Gene therapy, (46) 99
Heparin, (46) 107
Hepatic disposition of peptides, (46) 139
Hepatic endocytosis, (46) 139
Hepatic targeting, (46) 129
Human skin, (46) 205
Hydrocortisone, (46) 243
Hydrogel beads, (46) 273
Hydrophilic drug, (46) 279
IBD, (46) 75
IL-1ra, (46) 75
(Immuno)liposomes, (46) 165
Immunomodulation, (46) 165
In vivo, (46) 233
Inflammatory bowel disease, (46) 75
Interleukin-1 receptor antagonist, (46) 75
Intestine, (46) 39
Intracellular calcium, (46) 5
Isolated perfused liver preparation, (46) 139
Lipids, (46) 215
Liposome-gel, (46) 243
Liposomes, (46) 243
Liquid crystals, (46) 215
Liver, (46) 129
Lung, (46) 99
Lymphatic transfer, (46) 157
Lymphotropic carrier, (46) 157
Lysosomal proteolysis, (46) 139
Macromolecules, (46) 107
Macromolecule, (46) 157
Mannose receptor, (46) 139
Medipad, (46) 107
Membrane transport, (46) 31
Microemulsion, (46) 279
Microinfusor, (46) 107
Modified bile acids, (46) 17
Monoglycerides, (46) 215
Monoolein, (46) 215
Morphine, (46) 107
Mucus layer, (46) 233
Naproxen, (46) 139
Negatively charged albumins, (46) 139
(neo)-Glycoproteins, (46) 139
Neurotrophic factors, (46) 117
Oleic acid, (46) 279
Oligopeptide transporter, (46) 17
Oligopeptides, (46) 139
Oral insulin, (46) 89
Oral protein delivery, (46) 75
Paracellular permeability, (46) 5

Penetration modulation, (46) 279
Peptide delivery, (46) 5, (46) 17, (46) 39
Peptide drug delivery, (46) 59
Peptide, (46) 31, (46) 99, (46) 157
Peptidomimetics, (46) 31
Permeability, (46) 233
Pharmacokinetics, (46) 129, (46) 197
Piroxicam, (46) 205
Poly(ethylene glycol), (46) 253
Polymeric carriers, (46) 59
Protein, (46) 99, (46) 253
Proteolytic enzymes, (46) 39
Pulmonary, (46) 99
Rat colon, (46) 233
Rats, (46) 89
Retarded diffusion, (46) 243
Retention time for dyes, (46) 233
Serum half-life period, (46) 253
Signalling, (46) 5
Silicone membrane, (46) 205
Subcutaneous, (46) 107
Sugar recognition, (46) 129
Supersaturation, (46) 205
Sustained-release, (46) 197, (46) 215
Targeted skin delivery, (46) 243
Thermosensitive magnetoliposomes, (46) 263
Transferrin receptor, (46) 117
Vitamin K_5, (46) 129
Zero order delivery systems, (46) 197